Health Economics›Myelodysplastic syndrome›First-line therapy

First-line therapy

Myelodysplastic syndrome · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab monotherapy Variant #03	—	R 267 680	7d	~15.0 mo	—	~1	~R 267 680 PFS proxy · indirect	—
ATG (Rabbit) monotherapy Variant #01	—	R 190 734	18d	—	—	~1	~R 190 734 indirect	—
ATG (Horse) monotherapy Variant #01	—	R 116 960	17d	—	—	~1	~R 116 960 indirect	—
ATG (Horse) and Cyclosporine Variant #02	—	R 114 536	—	—	—	~1	~R 114 536 indirect	—
Decitabine monotherapy Variant #01	—	R 32 080	42d	—	10.1 mo	2	R 64 160 PFS proxy	1
Cyclosporine monotherapy Variant #03	—	R 29 855	—	—	—	~1	~R 29 855 indirect	—
Azacitidine monotherapy Variant #01	—	R 29 332	28d	—	24.5 mo	6	R 175 992 PFS proxy	1
Azacitidine and Vorinostat Variant #01 Partial	—	R 29 332	28d	—	—	~2	~R 58 664 indirect	—
Azacitidine and Lenalidomide Variant #01	—	R 23 129	28d	—	—	~7	~R 161 906 indirect	—
Temozolomide monotherapy Variant #02	—	R 3 434	14d	~4.0 mo	~16.3 mo	~27	~R 92 712 PFS proxy · indirect	10
Low-dose Cytarabine monotherapy (LoDAC) Variant #01	—	R 1 249	28d	—	~5.4 mo	~6	~R 7 491 PFS proxy · indirect	11
Decitabine and cedazuridine monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	~12	—	1
Best supportive care Partial	—	—	—	—	11.8 mo	—	—	2

14 of 14 regimens shown